Recurrent Renal Cell Carcinoma Downregulates MHC-I After Adjuvant Atezolizumab

While the incidence of kidney cancer remains stable or slightly increasing, mortality rates have declined by approximately 2% annually due to significant advances in systemic therapy [1]. For patients with high-risk localized disease, the surgical standard of care is often followed by adjuvant immunotherapy to delay recurrence, though clinical trial results in this setting have been notably heterogeneous [2, 3]. Currently, pembrolizumab remains the only immune checkpoint inhibitor with a clear recommendation for adjuvant use, as several other agents have failed to meet primary disease-free survival endpoints, including atezolizumab in the IMmotion010 trial which showed a hazard ratio of 0.93 (95% CI 0.75 to 1.15, p=0.50) [2, 4, 5]. Despite these interventions, many patients still experience disease relapse, and the optimal management of tumors that recur after exposure to checkpoint blockade remains a significant clinical challenge [6, 7]. A new study of 80 matched patient samples now provides a detailed characterization of how the genomic and transcriptomic landscape (the complete set of RNA transcripts produced by the genome) shifts between the primary tumor and the site of recurrence [8]. This analysis revealed that recurrent tumors exhibit an upregulation of signatures related to cell proliferation, fatty acid synthesis, and stromal biology (including the connective tissue matrix and fibroblasts that support tumor growth) compared to their primary counterparts [8].